Rachel Dahlborg

Suggest Changes
Learn More
Clinical investigations have demonstrated a link between use of the sulfone cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, and increased risk for atherothrombotic events. This increased risk was not(More)
  • 1